| Name |
Dimerix Limited (ASX:DXB) |
| Business Description |
Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology. Incorporated in 2004, Dimerix develops and commercialises pharmaceutical products for global markets using innovative receptor technology to identify and then develop drugs in areas with an unmet need. Each product is designed to be preferred by patients over current therapies.
Dimerix has used its proprietary Receptor-HIT technology to identify a new treatment (DMX-200) that may transform the lives of patients with Kidney Disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Read more about Dimerix
|
| Shares on Issue |
320,873,666 ordinary shares |
| Controlled Entities |
Dimerix Biosciences Pty Ltd (100% owned by Dimerix Limited) |
| CEO |
Dr Nina Webster
|
| Board of Directors |
Mr Hugh Alsop – Non-Executive Director
Dr Nina Webster – CEO & Managing Director
Dr Sonia Poli - Non-Executive Director
Clinton Snow - Non-Executive Director
Human Capital Committee and Audit & Risk Committee functions assumed by the Board |
| Company Secretary |
Mr Hamish George |
| Registered Office |
425 Smith Street, Fitzroy, Victoria 3065, AUSTRALIA |
| Phone |
+61 1300 813 321 |
| Email |
investor@dimerix.com
|
| Web |
https://dimerix.com/Opens in new window
|
| Share Registry |
Automic Pty Ltd.
Suite 1a, Level 1
7 Ventnor Avenue
West Perth, Western Australia 6005
Tel: +61 8 9324 2099
Fax: +61 8 9321 2337
Email:
hello@automic.com.au
Web:
https://automic.com.auOpens in new window
|
| Auditor |
Stantons International
Level 2, 1 Walker Avenue
West Perth, Western Australia 6005 |